secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001193125-22-217945
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru Q3 net loss $22.2M on 46% revenue decline; sabizabulin EUA under FDA, UK, EMA review
--------------------------------------------------------------------------------

- Net loss of $22.2M ($0.28 per share) vs $2.7M loss a year ago; revenue $9.6M vs $17.7M.
- Sabizabulin EUA submitted to FDA June 2022; UK MHRA granted expedited review; EMA Emergency Task Force reviewing for EU emergency use.
- Phase 3 COVID-19 trial showed 55.2% relative reduction in deaths; results published in NEJM Evidence.
- ENTADFI (tadalafil/finasteride) commercially launched for BPH; FC2 prescription sales down 50% due to telemedicine customer issues.
- Cash and equivalents $100.6M as of June 30, 2022, down from $122.4M at Sep 30, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312522217945/0001193125-22-217945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312522217945/d393861d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-217945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer